SGMTSagimet Biosciences Inc.

Nasdaq www.sagimet.com


$ 4.65 $ -0.38 (-7.57 %)    

Wednesday, 05-Jun-2024 15:59:55 EDT
QQQ $ 454.82 $ 9.16 (2.02 %)
DIA $ 398.57 $ 1.02 (0.26 %)
SPY $ 530.36 $ 6.28 (1.19 %)
TLT $ 91.26 $ 0.68 (0.73 %)
GLD $ 225.37 $ 2.55 (1.18 %)
$ 4.64
$ 4.86
$ 0.00 x 0
$ 0.00 x 0
$ 4.41 - $ 4.86
$ 2.13 - $ 20.71
953,365
na
134.74M
$ 4.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-21-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sagimet-biosciences-presented-data-from-fascinate-2-phase-2b-trial-of-denifanstat-versus-placebo-in-biopsy-confirmed-metabolic-dysfunction-associated-steatohepatitis-patients-at-the-european-association-for-the-study-of-the-liver-congress

Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population,...

 whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

 jmp-securities-reiterates-market-outperform-on-sagimet-biosciences-maintains-48-price-target

JMP Securities analyst Jonathan Wolleben reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and maintains...

 hc-wainwright--co-reiterates-buy-on-sagimet-biosciences-maintains-32-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.

 sagimet-biosciences-to-host-virtual-investor-and-analyst-day-on-inhibiting-fatty-acid-synthase-fasn-to-reduce-liver-fat-inflammation-and-fibrosis-in-mash-on-may-23-2024

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 goldman-sachs-maintains-buy-on-sagimet-biosciences-lowers-price-target-to-23

Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27...

 hc-wainwright--co-reiterates-buy-on-sagimet-biosciences-maintains-32-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $32 price target.

 sagimet-announces-oral-presentation-of-data-from-the-phase-2b-fascinate-2-study-of-denifanstat-in-mash-at-easl-international-liver-congress-2024

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 sagimet-biosciences-announces-appointment-of-thierry-chauche-as-chief-financial-officer-effective-may-6-2024

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 hc-wainwright--co-initiates-coverage-on-sagimet-biosciences-with-buy-rating-announces-price-target-of-32

HC Wainwright & Co. analyst Ed Arce initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announ...

 sagimet-biosciences-announces-completion-of-phase-1-hepatic-impairment-study-with-fasn-inhibitor-denifanstat

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 goldman-sachs-maintains-buy-on-sagimet-biosciences-lowers-price-target-to-27

Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $37...

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

 leerink-partners-initiates-coverage-on-sagimet-biosciences-with-outperform-rating-announces-price-target-of-26

Leerink Partners analyst Thomas Smith initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Outperform rating and a...

 jmp-securities-maintains-market-outperform-on-sagimet-biosciences-lowers-price-target-to-46

JMP Securities analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the...

 why-fmc-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION